7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Avenue Therapeutics, Inc
(NASDAQ:ATXI) 

ATXI stock logo

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderatel...

Founded: 2015
Full Time Employees: 4
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Avenue Therapeutics Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -4.79-4.11-3.42-2.74-2.05-1.37-0.680
Avenue Therapeutics Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -4.79-4.11-3.42-2.74-2.05-1.37-0.680
Avenue Therapeutics Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.531.061.592.112.643.173.7
Avenue Therapeutics (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -1.47-1.26-1.05-0.84-0.63-0.42-0.210
Avenue Therapeutics P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -55.62-44.16-32.69-21.23-9.761.713.1624.63
No extra charts and metrics for this ticker.